Tim D. Spelman
St Vincent's Hospital Melbourne
Fitzroy, VIC, Australia
Fitzroy, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 280 publications
A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease.
Journal: Science (New York, N.Y.)
Published: August 27, 2026
Management, Outcomes, and Factors Associated With Mortality and Treatment Failure of Non-Aspergillus Mold Infections: A Multicenter Study in Australia and New Zealand.
Journal: Open forum infectious diseases
Published: July 19, 2026
Development of a Digital Phenotype for Immune-Related Colitis.
Journal: JCO clinical cancer informatics
Published: June 16, 2026
Pre-emptive DPYD genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patients.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 21, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].
Journal: Multiple sclerosis and related disorders
Published: April 10, 2026
Predictive performance of an antibiotic precision dosing software program in critically ill adults with infection.
Journal: The Journal of antimicrobial chemotherapy
Published: February 25, 2026
Group education improves self-management of adrenal insufficiency in patients and their relative.
Journal: Endocrine connections
Published: February 17, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
Journal: Journal of neurology
Published: November 01, 2025
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 29, 2025
Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase.
Journal: Current neuropharmacology
Published: October 02, 2025
Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: September 16, 2025
Last Updated: 09/26/2026